Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381314 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02381314 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 24 participants.
The verdict
NCT02381314, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.
Interventions
- BIOLOGICAL enoblituzumab plus ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02381314
The ClinicalTrials.gov registry entry for NCT02381314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which enoblituzumab plus ipilimumab is the first listed.
NCT02381314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02381314 about?
NCT02381314 is a clinical study titled "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer". The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. Th...
What is the current status of trial NCT02381314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-03-26. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02381314?
The interventions under investigation include: enoblituzumab plus ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02381314?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.